Results 141 to 150 of about 36,124 (280)

Plasma EGFR mutation ctDNA dynamics in patients with advanced EGFR-mutated NSCLC treated with Icotinib: phase 2 multicenter trial result

Scientific Reports
Plasma epidermal growth factor receptor mutation (EGFRm) circulating tumor DNA (ctDNA) dynamics exhibit promise in predicting outcomes in patients with EGFRm-advanced non-small cell lung cancer (NSCLC).
Yaping Hong, Wu Zhuang, Jinhuo Lai, Haipeng Xu, Yueming He, Jinlan Lin, Qin Shi, Shengjia Chen, Zhangzhou Huang, Shijie Chen, Dongzhu Lu, Gen Lin, Yunjian Huang   +12 more
doaj   +1 more source

Assessing the exercise‐related kinetics of circulating cell‐free DNA, circulating tumour DNA, DNase I activity and cytokines in patients with solid tumours: A pilot study

Experimental Physiology, EarlyView.
Abstract Circulating cell‐free DNA (cfDNA), circulating tumour DNA (ctDNA) and inflammatory cytokines have prognostic and predictive value in oncology. However, the effects of acute exercise on cfDNA levels are unknown. Here, we explore the kinetics of cfDNA, ctDNA and cytokines upon an incremental exercise test in a pilot cohort of cancer patients ...
Elmo W. I. Neuberger, Alexandra Brahmer, Tobias Ehlert, Suzan Botzenhardt, Alfonso De Falco, Birgit Enders, Patricia S. Hähnel, Achim Heintz, Carl C. Schimanski, Thomas Kindler, Perikles Simon   +10 more
wiley   +1 more source

Levels of circulating tumor DNA correlate with tumor volume in gastro‐intestinal stromal tumors: an exploratory long‐term follow‐up study

Molecular Oncology
Patients with gastro‐intestinal stromal tumors (GISTs) undergoing tyrosine kinase inhibitor therapy are monitored with regular computed tomography (CT) scans, exposing patients to cumulative radiation. This exploratory study aimed to evaluate circulating
Roos F. Bleckman, Charlotte M. S. C. Haag, Naomi Rifaela, Gerrieke Beukema, Ron H. J. Mathijssen, Neeltje Steeghs, Hans Gelderblom, Ingrid M. E. Desar, Arjen Cleven, Arja terElst, Ed Schuuring, Anna K. L. Reyners   +11 more
doaj   +1 more source

Circulating Tumor DNA Predicts Response After Definitive Radiation Therapy for Merkel Cell Carcinoma

Advances in Radiation Oncology
Purpose: Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer with a high recurrence rate. Circulating tumor DNA (ctDNA) assays are increasingly used to assess treatment response and detect recurrence.
Kyle Murchison, BS, Anthony Camargo, BA, Danielle Margalit, MD, Jonathan D. Schoenfeld, MD, MPH, Roy Tishler, MD, Karam Khaddour, MD, Manisha Thakuria, MD, Ann W. Silk, MD   +7 more
doaj   +1 more source

Molecular–clinical characteristics and treatment outcomes in 163 metastatic colorectal neuroendocrine carcinomas with a comparison to colorectal adenocarcinomas

International Journal of Cancer, Volume 158, Issue 12, Page 3217-3231, 15 June 2026.
What's new? Colorectal neuroendocrine carcinoma (CR‐NEC) is a rare digestive neuroendocrine neoplasm that frequently exhibits an adenocarcinoma component. Nonetheless, the underlying biology of CR‐NEC remains poorly understood. This study examined molecular and clinical features and palliative chemotherapy outcomes of metastatic CR‐NEC, with comparison
Siren Morken, Seppo W. Langer, Geir Olav Hjortland, Anna Sundlöv, Eva Hofsli, Morten Ladekarl, Elizaveta Tabaksblat, Lene Weber Vestermark, Johanna Svensson, Ulrich Knigge, Luís Nunes, Bengt Glimelius, Per Pfeiffer, Kristine Aasebø, Jörg Assmus, Erik Vassella, Inger Marie Bowitz Lothe, Anne Couvelard, Aurel Perren, Stian Knappskog, Halfdan Sorbye   +20 more
wiley   +1 more source

El papel de la enfermería en la Biopsia Líquida [PDF]

, 2019
Introducción: El cáncer sigue constituyendo una de las principales causas de morbilidad del mundo. Las estimaciones poblacionales indican que el número de casos probablemente aumente a un 70% en las próximas décadas. Desde el año 2000 en nuestro país, el
Villaverde Hueso, María
core  

Oxidative Stress and DNA Epigenetic Modifications in Cancer: Mechanisms and Targeted Therapeutics

MedComm – Oncology, Volume 5, Issue 2, June 2026.
Reactive oxygen species (ROS) modulate DNA methyltransferases (DNMTs), ten‐eleven translocation family proteins (TETs) and their cofactors, reshaping 5‐methylcytosine (5mC)/5‐hydroxymethylcytosine (5hmC)/5‐formylcytosine (5fC) landscapes and gene expression in cancer cells. In turn, epigenetic control of antioxidant and metabolic pathways feeds back on
Xishan Yang, Qitai Chen, YuJie Yu, Yi Zang, Rujia Zheng, Zhe Zhang, Shuaijun Lu, Li Zhou   +7 more
wiley   +1 more source

The prognostic and clinical utility of circulating tumor DNA in diffuse large B-cell lymphoma: a systematic review and meta-analysis

npj Precision Oncology
Circulating tumor DNA (ctDNA) provides a minimally invasive tool for assessing tumor burden and genetic evolution in diffuse large B-cell lymphoma (DLBCL).
Shayan Forghani, Amirhossein Shahsavand, Reza Samiee, Mohammadamin Kharaghani, Azadeh Kiumarsi, Fatemeh Mahdavi Sabet, Saba Akbarzadeh, Sajjad Fattahniya, Mohammadreza Rostami, Soroush Rad, Amir Hossein Mirhosseini, Tahereh Rostami, Ghasem Janbabai   +12 more
doaj   +1 more source

Clinicopathological characteristics of patients with inoperable non‐small cell lung cancer harboring circulating NRF2 pathway mutations

The Journal of Pathology, Volume 269, Issue 2, Page 164-181, June 2026.
Abstract Lung cancer is the leading cause of global cancer‐related morbidity and mortality, with tobacco smoking as its strongest risk factor. Nuclear factor erythroid 2‐related factor 2 (NRF2) is a redox‐regulated transcription factor frequently dysregulated in non‐small cell lung cancer (NSCLC), leading to aggressive disease and resistance to therapy.
Jouni Härkönen, Satu Tiainen, Jouni Kujala, Linnea Muhonen, Ponnuswamy Mohanasundaram, Tuomas Tikkanen, Ina Pöhner, Tommi Patinen, Simone Adinolfi, Juha P Väyrynen, Päivi Auvinen, Arto Mannermaa, Petri Pölönen, Tuomas Rauramaa, Anna‐Liisa Levonen   +14 more
wiley   +1 more source

The Prognostic Significance of Radiographic Progression Without PSA Progression in Patients With Metastatic Hormone‐Sensitive Prostate Cancer Treated With First‐Line ARPI Therapy

The Prostate, Volume 86, Issue 8, Page 882-890, June 2026.
ABSTRACT Background Radiographic progression (RP) without prostate‐specific antigen (PSA) elevation has emerged as a clinically important pattern in the androgen receptor pathway inhibitors (ARPI) era, but its prevalence and prognostic significance in real‐world metastatic hormone‐sensitive prostate cancer (mHSPC) cohorts remain unclear.
Takeshi Tsutsumi, Shogo Yamazaki, Takuya Matsuda, Takuya Tsujino, Taizo Uchimoto, Takafumi Yanagisawa, Keiichiro Mori, Wataru Fukuokaya, Fumihiko Urabe, Masanobu Saruta, Atsuhiko Yoshizawa, Shingo Toyoda, Saizo Fujimoto, Kyosuke Nishio, Moritoshi Sakamoto, Tatsuo Fukushima, Ko Nakamura, Kazuki Nishimura, Keita Nakamori, Tomohisa Matsunaga, Yuki Yoshikawa, Ryoichi Maenosono, Kiyoshi Takahara, Teruo Inamoto, Takahiro Kimura, Kazutoshi Fujita, Kazumasa Komura, Haruhito Azuma   +27 more
wiley   +1 more source